Image (61c99eec 4bd5 4f46 931b 26b58f67e6a5 546 2)
Topiramate Tablet, Film Coated
Product Images NDC 68071-4760
5 FDA label images from Nucare Pharmaceuticals,inc. · Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Topiramate (NDC 68071-4760). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Pdp (68071 4760 03 U28)
Label for Topiramate 50 mg film-coated tablets from NuCare Pharmaceuticals, Inc. The label shows a package size of 30 tablets, with each tablet containing 50 mg of topiramate. The tablets are described as round, white/off-white with debossed markings 'U' on one side and '116' on the other. Includes NDC 68071-4760-3 and a note that the product is Rx only.*
Image (74b72b34 291e 4a5c 96b1 7f05d629bd47 01)
Chemical structure of topiramate, showing its molecular configuration with functional groups including sulfonamide, methyl, and cyclic ether components.*
Image (74b72b34 291e 4a5c 96b1 7f05d629bd47 02)
A cumulative rates curve graph comparing time to first seizure over 500 days for two dosages of topiramate (50 mg/day and 400 mg/day). The x-axis represents time in days, and the y-axis indicates cumulative rates for time to first seizure, with patient numbers noted for each dosage group.*
Image (74b72b34 291e 4a5c 96b1 7f05d629bd47 03)
A bar graph comparing the change from baseline to double-blind phase in average monthly migraine period rate with placebo and varying doses of topiramate (50 mg/day, 100 mg/day, and 200 mg/day) across two studies. The graph shows mean reductions with standard error bars, indicating statistically significant decreases in migraine rates at higher doses of topiramate compared to placebo.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
